Sector News

TapImmune to merge with Baylor adoptive T-cell startup Marker

May 16, 2018
Life sciences

TapImmune is planning to merge with T-cell therapy startup Marker Therapeutics. The agreement will give TapImmune control of adoptive T-cell therapies designed to provide more durable responses than CAR-Ts and other genetically engineered treatments.

Marker, a Baylor College of Medicine spinout, is based on technology for selectively expanding a patent’s own T cells. The result is T cells that target multiple tumor-expressed antigens, specifically MAGE-A4, PRAME, survivin, NY-ESO-1 and SSX2. In an early-phase lymphoma trial, the cells triggered complete responses in more than half the participants, according to TapImmune.

Jacksonville, Florida-based TapImmune is getting its hands on the technology by offering shares and warrants to Marker shareholders. If the deal goes through, Marker shareholders will own half of the combined company.

Marker largely flew under the radar during its three-year existence. A report from a Minnesotan medical trade group stated the firm raised $20 million last year but the financing received minimal coverage. Similarly, company co-founder Ann Leen, Ph.D., presented data on non-engineered T cells at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium without capturing the sector’s attention.

The data came from Hodgkin lymphoma patients who took multi-tumor-associated antigen-specific T cells. Of the 12 patients with active disease, five had complete responses. Some patients who took the cells have been relapse-free for more than two years, emboldening TapImmune to talk up the potential to better CAR-Ts.

TapImmune is a long way from having the data to put the cells in the same league as CAR-Ts but efforts to validate the tumor-associated antigen approach are underway.

Researchers at Baylor are testing tumor-associated antigen-specific cytotoxic T lymphocytes in a few clinical trials featuring patients with lymphoma, leukemia or myelodysplastic syndrome. TapImmune is set to gain a connection to Baylor’s research through the merger. The plan is to form a strategic alliance that covers research, manufacturing support and early-phase clinical trials.

TapImmune is also planning to raise money to support its expanded pipeline. The goal is to raise enough money to take the combined company into 2020.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach